# Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)

> **NCT07527195** · PHASE1 · RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 100 (estimated)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Cagrilintide
- **DRUG:** Semaglutide
- **DRUG:** Placebo cagrilintide
- **DRUG:** Placebo semaglutide

## Key facts

- **NCT ID:** NCT07527195
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-10
- **Primary completion:** 2028-04-28
- **Final completion:** 2028-06-09
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07527195

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07527195, "Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)". Retrieved via AI Analytics 2026-08-02 from https://api.ai-analytics.org/clinical/NCT07527195. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*